The University of Reading has developed the TRIPLEcheck assay to personalize antiplatelet therapy by assessing platelet reactivity, with a 400-patient clinical trial underway.
The quantitative measurement test is designed to aid in myocardial infarction diagnosis using human plasma samples.
Roche’s Tina-quant Lp(a) Gen.2 Molarity assay received FDA 510(k) clearance, supporting more precise cardiovascular risk assessment.
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways.
Read More
A new blood test can diagnose heart attacks in just 5-7 minutes, with potential applications for both clinical settings and at-home use.
Read More
The Atellica IM Troponin I test received clearance for predicting cardiac events after initial symptoms of acute coronary syndrome.
Read More
Researchers developed a gene mutation test that predicts the severity of Long QT syndrome, helping assess the risk of sudden cardiac death.
Read More
A study found that elevated blood levels of LDL cholesterol, Lp(a), and CRP significantly increase long-term cardiovascular risk.
Read More
A new review finds that 20% of the global population carries a genetic risk for cardiovascular diseases due to high levels of lipoprotein(a).
Read More
ADLM released guidelines to standardize lipid testing, aiming to improve the effectiveness of cardiovascular disease risk assessment.
Read More
Researchers developed a POC electrochemical biosensor prototype designed to provide at-home screening capabilities for heart failure.
Read More
A study reveals that lipid panels may not fully capture the risk of cholesterol-related heart disease, highlighting a need for apoB testing.
Read More
Prevencio received a patent for its AI-powered blood test which accurately assesses the risk of obstructive coronary artery disease.
Read More
Researchers developed a machine learning method that utilizes deep learning and video microscopy to automate the analysis of heart dynamics.
Read More
Siemens Healthineers introduced the NT-proBNPII assay to its Atellica Solution, enhancing rapid diagnostic capabilities for heart failure.
Read More
Roche announced that its Tina-quant lipoprotein Lp(a) RxDx assay received Breakthrough Device Designation from the FDA.
Read More
Researchers developed a genetic testing procedure that can identify patients at high risk for cardiovascular diseases.
Read More
Analytics for Life and CorVista Health announced U.S. FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module
Read More